QGEN•Crown NL Bidco agreed to acquire all Qiagen shares for EUR 46.50 each in cash. The deal requires acceptance of at least 50% plus one share and regulatory clearances.
Qiagen’s managing and supervisory boards unanimously support the transaction. Crown NL Bidco has committed EUR 5.97 billion in equity financing, with debt commitments covering the remaining funding needs; closing is not conditional on financing. The buyer aims to obtain full ownership and delist Qiagen shares from the New York and Frankfurt stock exchanges. Specified circumstances could trigger a EUR 150 million termination fee for Qiagen or a EUR 300 million fee for the buyer if regulatory conditions fail.
